A.R.T. Advisors’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

A.R.T. Advisors’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-5,031	Closed	-$48K	–	1879
2019 Q2	$48K	Sell	5,031 -538	-10%	-$9.9K	﹤0.01%	1249
2019 Q1	$149K	Buy	5,569 +850	+18%	+$21.6K	0.01%	1119
2018 Q4	$107K	Sell	4,719 -234	-5%	-$9.15K	0.01%	1157
2018 Q3	$273K	Sell	4,953 -3,764	-43%	-$240K	0.01%	1081
2018 Q2	$622K	Sell	8,717 -4,428	-34%	-$313K	0.03%	834
2018 Q1	$807K	Buy	+13,145	New	+$1.15M	0.03%	740
2017 Q4	–	Sell	-923	Closed	-$126K	–	1802
2017 Q3	$126K	Sell	923 -5,548	-86%	-$742K	0.01%	1193
2017 Q2	$922K	Buy	6,471 +4,437	+218%	+$686K	0.05%	556
2017 Q1	$373K	Buy	2,034 +739	+57%	+$82.8K	0.02%	910
2016 Q4	$104K	Buy	+1,295	New	+$102K	0.01%	1143
2016 Q1	–	Sell	-17,676	Closed	-$3.54M	–	1772
2015 Q4	$3.54M	Buy	17,676 +7,491	+74%	+$1.49M	0.17%	143
2015 Q3	$1.52M	Buy	+10,185	New	+$7.48M	0.06%	483
2013 Q3	–	Sell	-588	Closed	-$82K	–	1576
2013 Q2	$82K	Buy	+588	New	+$93.1K	﹤0.01%	1257

Other funds holding TTPH

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

A.R.T. Advisors's TTPH Position: Q3 2019 in Review

A.R.T. Advisors sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2019, closing a stake of 5,031 shares — an estimated $48K sold.

A.R.T. Advisors first reported a position in TTPH in Q2 2013 and held it in 13 quarters. The position peaked at $3.54M in Q4 2015. 26 funds tracked by Wall St. Rank hold TTPH as of Q3 2019.

A.R.T. Advisors reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
A.R.T. Advisors sold 5,031 Tetraphase Pharmaceuticals, Inc. shares in Q3 2019, an estimated $48K.
A.R.T. Advisors first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2013 and held it in 13 quarters.
A.R.T. Advisors's Tetraphase Pharmaceuticals, Inc. position peaked at $3.54M in Q4 2015.
26 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.